Radioimmunotherapy of Non-Hodgkin’s Lymphoma

TO THE EDITOR: The contrast between 2 papers on this topic published side by side in The Journal of Nuclear Medicine is quite striking. The first, by Koral et al. ([1][1]), concentrates on tumor dosimetry and response using 131I-tositumomab therapy. The second, by Wiseman et al. ([2][2]) on